Drug
Sasanlimab clinical trials
Also written PF-06801591.
- studies test it
- 11
- open now
- 2
- in phase 3
- 1
- first study started
- 2016
Keep track of what changes. Save the sasanlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
11 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 4
Pfizer (7) · The Methodist Hospital Research Institute (1) · Maastricht University Medical Center (1) · National Cancer Institute (NCI) (1) · Stephanie Berg (1)
Often tested with
Tested in the same studies.
BCG Vaccine (1) · Palbociclib (1) · Axitinib (1) · Encorafenib (1) · Binimetinib (1)
Studies
Open first, then newest update. How each study uses sasanlimab is read from its arms, and is right about nine times in ten.
Testing it · 11
- Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)RecruitingPhase 1/2National Cancer Institute (NCI)NCT05665361Written as Sasanlimab
- A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell CarcinomaRecruitingPhase 2Stephanie BergNCT07123090Written as Sasanlimab
- A Study of Sasanlimab in People With Non-muscle Invasive Bladder CancerActive, not recruitingPhase 3PfizerNCT04165317Written as PF-06801591
- Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced MalignanciesCompletedPhase 1/2PfizerNCT04181788Written as PF-06801591
- A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic MalignanciesTerminatedPhase 1PfizerNCT06974734Written as sasanlimab
- PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid TumorsTerminatedPhase 1PfizerNCT05233436Written as Sasanlimab
- Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)TerminatedPhase 1/2PfizerNCT04585815Written as Sasanlimab
- Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder CancerActive, not recruitingPhase 2The Methodist Hospital Research InstituteNCT05241340Written as Sasanlimab
- Ketohexokinase Inhibition in Hereditary Fructose IntoleranceCompletedPhase 2Maastricht University Medical CenterNCT06089265Written as PF-06801591
- PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)WithdrawnPhase 1PfizerNCT05259397Written as sasanlimab
- A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid TumorsCompletedPhase 1PfizerNCT02573259Written as PF-06801591
Given in every arm · 14 — sasanlimab is usual care beside what is tested
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder CancerRecruitingPhase 1PfizerNCT07206225Written as Sasanlimab
- Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTorNot yet recruitingPhase 2/3Radboud University Medical CenterNCT06218069Written as Sasanlimab
- A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.Active, not recruitingPhase 1PfizerNCT06447662Written as Sasanlimab
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.TerminatedPhase 1PfizerNCT04458259Written as Sasanlimab
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.TerminatedPhase 1PfizerNCT06704724Written as Sasanlimab
- A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced CancersTerminatedPhase 1PfizerNCT06870487Written as Sasanlimab
- A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With CancerTerminatedPhase 1PfizerNCT06580938Written as Sasanlimab
- A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedPhase 1PfizerNCT06546553Written as sasanlimab
- A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedPhase 1PfizerNCT06285097Written as Sasanlimab
- Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.TerminatedPhase 1PfizerNCT04152018Written as PF-06801591
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedPhase 1Seagen Inc.NCT04254107Written as sasanlimab
- A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In CombinationTerminatedPhase 1PfizerNCT06448364Written as sasanlimab
- Study of PF-07263689 in Participants With Selected Advanced Solid TumorsTerminatedPhase 1PfizerNCT05061537Written as Sasanlimab
- A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)TerminatedPhase 1PfizerNCT02616185Written as PF-06801591
Codes
What other systems call sasanlimab · ClinicalTrials.gg INT017226
- UNII (FDA) LZZ0IC2EWPSASANLIMABOne source FDA
- NCI Thesaurus C124058SasanlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LZZ0IC2EWP | SASANLIMAB | One source FDA |
| NCI Thesaurus | C124058 | Sasanlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.